1. Kuo CF, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015 Nov;11(11):649-62. 2. Khanna D, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-46. 3. Department of Health Annual Report 2000-2001. 4. Lai SW, et al. Prevalence of gout and hyperuricemia in Taiwan: a hospital-based, cross-sectional study. South Med J. 2009 Jul;102(7):772-3. 5. Dalbeth N, et al. Gout. Lancet. 2016;388(10055):2039-2052. 6. Gout. 2015. (Accessed 26 April, 2017, at http://www.nhs.uk/conditions/Gout/Pages/introduction.aspx.) 7. 痛風. 2015. (Accessed 26 April, 2017, at http://www3.ha.org.hk/dic/sdn_07_01.html.) 8. Ben Salem C, et al. Drug-induced hyperuricaemia and gout. Rheumatology (Oxford). 2016 Aug 7. [Epub ahead of print]. 9. Li EK. Gout: a review of its aetiology and treatment. Hong Kong Med J. 2004;10(4):261-70. 10. Reginato AM, et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012;8(10):610-21. 11. Hainer BL, et al. Diagnosis, treatment, and prevention of gout. Am Fam Physician. 2014 Dec 15;90(12):831-6. 12. Gout. 2014. (Accessed 26 April, 2017, at https://my.clevelandclinic.org/health/articles/gout.) 13. Chhana A, Dalbeth N. Structural joint damage in gout. Rheum Dis Clin North Am. 2014;40(2):291-309. 14. Gout – Complications. 2015. (Accessed 26 April, 2017, at http://www.nhs.uk/conditions/Gout/Pages/Complications.aspx.) 15. Kim S, Chang Y, Yun KE, et al. Development of Nephrolithiasis in Asymp- tomatic Hyperuricemia: A Cohort Study. American journal of kidney diseases : the official journal of the National Kidney Foundation 2017. doi: 10.1053/j.ajkd.2017.01.053. 16. Mallat SG, et al. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. Curr Hypertens Rep. 2016;18(10):74. 17. Grassi D, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432-8. 18. Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. 19. Qaseem A, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American Col- lege of Physicians. Ann Intern Med. 2017;166(1):58-68. 20. Borghi C, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-41. 21. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum. 1986;29(1):82-7.